Habib Rahban

Habib Rahban

Auto-generated profile, based on publicly available information

Habib Rahban

Cardiovascular Research Foundation of Southern California Beverly Hills CA USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Clinical Transplantation
Verified
Journal Article
Closed access
MSMahdi Shadnoush
Mahdi Shadnoush
MLMarzieh Latifi
Marzieh Latifi
HRHabib Rahban
Habib Rahban
EPElahe Pourhosein
Elahe Pourhosein
ASAlireza Shadnoush
Alireza Shadnoush
SDSanaz Dehghani
Sanaz Dehghani

19 April 2025 in Clinical Cardiology
Verified
Journal Article
Open access
KTKiarash Tavakoli
Kiarash Tavakoli
NMNegin Sadat Hosseini Mohammadi
Negin Sadat Hosseini Mohammadi
PBPegah Bahiraie
Pegah Bahiraie
SSSahar Saeidi
Sahar Saeidi
FSFarhad Shaker
Farhad Shaker
KHKaveh Hosseini
Kaveh Hosseini
Background: Comparisons of outcomes after transcatheter aortic valve replacement with balloon‐expandable (BEV) versus self‐expanding (SEV) valves are limited.Hypothesis: This study aimed to compare clinical and hemodynamic outcomes of BEV and SEV at short‐term (30 days), midterm (1 year), and long‐term (> 1 year) endpoints.Methods: PubMed, Embase, Scopus, and Cochrane Library databases were searched until July 2024 for randomized controlled trials. Random‐effect model (DerSimonian–Laird method) was used to pool the risk ratios (RR), mean differences, and 95% confidence intervals (CI).Results: A total of 10 studies comprising 4325 patients (2295 BEV, 2030 SEV) were included. In short‐term, cardiovascular (RR: 0.56, 95% CI: 0.36–0.87) and all‐cause mortality (RR: 0.54, 95% CI: 0.35–0.81) were lower in the BEV group. Risk of moderate to severe paravalvular leak (PVL) was lower among BEV patients in short‐term (RR: 0.28, 95% CI: 0.17–0.49) and long‐term (RR: 0.28, 95% CI: 0.1–0.79). A limited number of studies showed a greater risk of clinical valve thrombosis on BEV in midterm and long‐term. The need for permanent pacemaker implantation was lower in BEV at both short‐term (RR: 0.56, 95% CI: 0.37–0.87), and midterm (RR: 0.78, 95% CI: 0.64–0.94). The SEV group had a larger effective orifice area with lower mean transvalvular pressure gradient at all endpoints.Conclusions: BEV is associated with reduced risk of clinical outcomes in short‐term; however, most differences diminish in longer evaluations, except for moderate to severe PVL, which remains elevated for SEV. SEVs had better hemodynamic results and lower risk of clinical valve thrombosis.